Lirilumab
Based on 3 publication(s) in Google Scholar
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 96.80%
- CAS No.: 1000676-41-4
- 분자량:145.52 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Lirilumab
More
Biological Activity
Human IgG4 kappa
Human
KIR
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rag1KO-Tg KIR mice injected with tumor cells[2]
-
Dosage:15 mg/kg
-
Administration:intravenous injection; 15 mg/kg; once
-
Result:Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized KIR2DL1 Protein, Human (HEK293, His) can bind Lirilumab. The EC50 for this effect is 16.59 ng/mL.
Chemical Information
-
CAS No. 1000676-41-4
-
Appearance Liquid
-
분자량 145.52 kDa
-
Color Colorless to light yellow
-
SMILES
[Lirilumab]
-
Synonyms
IPH2102
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides. [Abstract]2024 Jan 25;15(1):752. PMID: 38272918 -
Cell Death Dis
Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma. [Abstract]2025 Nov 28;16(1):865. PMID: 41315184 -
J Immunother Cancer
2024 Jul 1; 12(7): e009410. PMID: 38955423
순도&문서
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478. [Content Brief]
[2]. Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lirilumab Related Classifications
HY-P99208 Related Classifications
Powered by Bioz